Devi, S.
09/388090


```
      23mar01 11:28:38 User219783 Session D1693.1

SYSTEM:OS  - DIALOG OneSearch
  File  35:Dissertation Abstracts Online  1861-2001/Mar
        (c) 2001 UMI
  File  65:Inside Conferences  1993-2001/Mar W3
        (c) 2001 BLDSC all rts. reserv.
*File  65: CD=2000 and CY=2000 are not fully functioning.
Please see Help News65 for details.
  File  77:Conference Papers Index  1973-2001/Mar
        (c) 2001 Cambridge Sci Abs
  File 144:Pascal  1973-2001/Mar W3
        (c) 2001 INIST/CNRS
  File 266:FEDRIP  2001/Mar
        Comp & dist by NTIS, Intl Copyright All Rights Res
  File 440:Current Contents Search(R)  1990-2001/Apr W1
        (c) 2001 Inst for Sci Info
*File 440: Please note new price changes effective January 1, 2001.
See Help Rates440 for details.
  File 348:EUROPEAN PATENTS  1978-2001/Mar W02
        (c) 2001 European Patent Office
  File 357:Derwent Biotechnology Abs  1982-2001/Mar B2
        (c) 2001 Derwent Publ Ltd
*File 357: Price changes as of 1/1/01. Please see HELP RATES 357.
  File 113:European R&D Database  1997
        (c)1997 Reed-Elsevier(UK)Ltd All rts reserv
*File 113: This file is closed (no updates)

      Set  Items  Description
      ---  -----  -----------
? ds; t 4/3,ab/1-32

Set     Items   Description
S1      43261   (SDS OR (NA OR SODIUM)(W)DODECYL)(2W)((POLYACRYLAMIDE OR P-
             OLY(W)(ACRYLAMIDE OR ACRYL(W)AMIDE))(2W)ELECTROPHOR? OR PAGE)
S2         82   S1 AND (NEISSERIA(5N)(POLYPEPTIDE? ? OR POLYPROTEIN? ? OR -
              PROTEIN? ? OR PEPTIDE? ?))
S3         36   S2 AND (DNA OR DEOXYRIBONUCLEIC OR DEOXY(W)RIBONUCLEIC OR -
              NUCLEOTIDE? ?)
S4         32   RD (unique items)
>>>No matching display code(s) found in file(s): 65, 113

 4/3,AB/1     (Item 1 from file: 35)
DIALOG(R)File  35:Dissertation Abstracts Online
(c) 2001 UMI. All rts. reserv.

01237367  AAD9226016
ISOLATION AND CHARACTERIZATION OF THE GENE ENCODING THE MAJOR ANAEROBICALLY
INDUCED OUTER MEMBRANE *PROTEIN"** OF *NEISSERIA"** GONORRHOEAE
                          Searcher    :      Shears    308-4994
```

Author: HOEHN, GERARD THOMAS
Degree: PH.D.
Year: 1992
Corporate Source/Institution: THE UNIVERSITY OF ROCHESTER (0188)
Source: VOLUME 53/04-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 1701. 205 PAGES

When grown anaerobically, Neisseria gonorrhoeae, the etiologic agent of the sexually transmitted disease gonorrhea, induces the synthesis of several outer membrane proteins. One of these, designated Pan 1, is recognized by sera from women with gonococcal infection. The presence of antibodies directed against the Pan 1 protein suggests that N. gonorrhoeae grows anaerobically in vivo and that Pan1 may be involved in infection.

To analyze the Pan 1 protein, mouse polyclonal anti-Pan 1 antiserum was generated from gel-purified Pan 1. Specificity of the antiserum to Pan 1 was demonstrated by immunoblot analysis of outer membranes prepared from aerobically or anaerobically grown cells. On silver-stained *SDS"**-*PAGE"** gels, Pan 1 appeared as an intense and diffuse band, suggesting the presence of an N-terminal modification. When N. gonorrhoeae was grown anaerobically with ($\sp3$-H) palmitic acid, label was specifically incorporated into the Pan 1 protein, indicating that it is a lipoprotein.

The Pan 1 gene (aniA) was cloned by screening a phage expression library with anti-Pan 1 antiserum. Three immunoreactive clones containing overlapping *DNA"** fragments were isolated. All clones were able to adsorb anti-Pan 1 antibody that, when eluted from the plaques, reacted to Pan 1. Immunoblot analysis of recombinant lysogens showed that two of the clones made fusion proteins that reacted with anti-Pan 1 antiserum. Northern blot analysis revealed that aniA mRNA is only made anaerobically, confirming that the clones code for an anaerobically induced protein.

The sequence of the aniA gene predicted a mature protein of 39 kDa with a lipoprotein leader consensus sequence. The Pan1 protein showed extensive homology at the N-terminus to two gonococcal lipoproteins, H.8 and azurin. Primer extension analysis demonstrated the presence of two transcriptional start sites: one promoter with homology to the $-$10 region of $\sigma\sp{70}$ promoters, and another promoter with extensive homology to the $-$10 and $-$35 regions of E. coli "gearbox" promoters.

The distribution of Pan1 among *Neisseria"** species was investigated at the *protein"** and molecular level. The aniA gene was present and expressed in all N. gonorrhoeae strains tested. In N. meningitidis, all strains had a copy of the aniA gene, but expressed little, if any Pan1 *protein"**. Several commensal *Neisseria"** species contained the aniA gene and expressed Pan1 protein.

4/3,AB/2 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal

14332486 PASCAL No.: 99-0541000

Neisseria gonorrhoeae bacterioferritin : structural heterogeneity, involvement in iron storage and protection against oxidative stress

CHEN C Y; MORSE S A
Division of AIDS, Sexually Transmitted Diseases and Tuberculosis Laboratory Research, National Centers for Infectious Disease, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, United States

Journal: Microbiology : (Reading), 1999, 145 (p.10) 2967-2975
Language: English

The iron-storage *protein"** bacterioferritin (Bfr) from *Neisseria"** gonorrhoeae strain F62 was identified in cell-free extracts and subsequently purified by column chromatography. Gonococcal Bfr had an estimated molecular mass of 400 kDa by gel filtration; however, analysis by *SDS"**-*PAGE"** revealed that it was composed of 18 kDa (BfrA) and 22 kDa (BfrB) subunits. *DNA"** encoding BfrB was amplified by PCR using degenerate primers derived from the N-terminal amino acid sequence of BfrB and from a C-terminal amino acid sequence of Escherichia coli Bfr. The *DNA"** sequence of bfrA was subsequently obtained by genome walking using single-specific-primer PCR. The two Bfr genes were located in tandem with an intervening gap of 27 bp. A potential Fur-binding sequence (12 of 19 bp identical to the consensus neisserial fur sequence) was located within the 5' flanking region of bfrA in front of a putative -35 hexamer. The homology between the *DNA"** sequences of bfrA and bfrB was 55.7%; the deduced amino acid sequences of BfrA (154 residues) and BfrB (157 residues) showed 39.7% identity, and showed 41.3% and 56.1% identity, respectively, to E. coli Bfr. Expression of recombinant BfrA and BfrB in E. coli strain DH5 alpha was detected on Western blots probed with polyclonal anti-E. coli Bfr antiserum. Most Bfrs are homopolymers with identical subunits; however, the evidence presented here suggests that gonococcal Bfr was composed of two similar but not identical subunits, both of which appear to be required for the formation of a functional Bfr. A Bfr-deficient mutant was constructed by inserting the OMEGA fragment into the BfrB gene. The growth of the BfrB-deficient mutant in complex medium was reduced under iron-limited conditions. The BfrB-deficient mutant was also more sensitive to killing by H SUB 2 O SUB 2 and paraquat than the isogenic parent strain. These results demonstrate that gonococcal Bfr plays an important role in iron storage and protection from iron-mediated oxidative stress.

4/3,AB/3 (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

11059804 GENUINE ARTICLE#: 251JL NUMBER OF REFERENCES: 40
TITLE: Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli
AUTHOR(S): Nopponpunth V; Sirawaraporn W; Greene PJ; Santi DV (REPRINT)
Searcher : Shears 308-4994

AUTHOR(S) E-MAIL: santi@cgl.ucsf.edu
CORPORATE SOURCE: Univ Calif San Francisco, Dept Biochem & Biophys, /San Francisco//CA/94143 (REPRINT); Univ Calif San Francisco, Dept Biochem & Biophys, /San Francisco//CA/94143; Univ Calif San Francisco, Dept Pharmaceut Chem, /San Francisco//CA/94143; Mahidol Univ, Dept Biochem, /Bangkok 10400//Thailand/
PUBLICATION TYPE: JOURNAL
PUBLICATION: JOURNAL OF BACTERIOLOGY, 1999, V181, N21 (NOV), P6814-6821
PUBLISHER: AMER SOC MICROBIOLOGY, 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
ISSN: 0021-9193
LANGUAGE: English DOCUMENT TYPE: ARTICLE
ABSTRACT: The genes for dihydropteroate synthase of Mycobacterium tuberculosis and Mycobacterium leprae were isolated by hybridization with probes amplified from the genomic *DNA"** libraries. *DNA"** sequencing revealed an open reading frame of 840 bp encoding a protein of 280 amino acids for M. tuberculosis dihydropteroate synthase and an open reading frame of 852 bp encoding a protein of 284 amino acids for M. leprae dihydropteroate synthase. The dihydropteroate synthases were expressed under control of the T5 promoter in a dihydropteroate synthase-deficient strain of Escherichia coli. Using three chromatography steps, we purified both M. tuberculosis and M. leprae dihydropteroate synthases to >98% homogeneity. *Sodium"** *dodecyl"** sulfate-*polyacrylamide"** gel *electrophoresis"** revealed molecular masses of 29 kDa for M. tuberculosis dihydropteroate synthase and 30 kDa for M. leprae dihydropteroate synthase. Gel filtration of both enzymes showed a molecular mass of ca. 60 kDa, indicating that the native enzymes exist as dimers of two identical subunits. Steady-state kinetic parameters for dihydropteroate synthases from both M. tuberculosis and M. leprae were determined. Representative sulfonamides and dapsone were potent inhibitors of the mycobacterial dihydropteroate synthases, but the antimycobacterial agent p-aminosalicylate, a putative dihydropteroate synthase inhibitor, was a poor inhibitor of the enzymes.

4/3,AB/4 (Item 2 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

08050716 GENUINE ARTICLE#: VZ989 NUMBER OF REFERENCES: 22
TITLE: Cloning, sequencing and expression of an Eikenella corrodens gene encoding a component protein of the lectin-like adhesin complex
AUTHOR(S): Yumoto H (REPRINT); Azakami H; Nakae H; Matsuo T; Ebisu S
CORPORATE SOURCE: UNIV TOKUSHIMA,SCH DENT, DEPT CONSERVAT DENT, 3-18-15 KURAMOTO CHO/TOKUSHIMA 770//JAPAN/ (REPRINT)
PUBLICATION TYPE: JOURNAL
PUBLICATION: GENE, 1996, V183, N1-2 (DEC 12), P115-121
PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS

ISSN: 0378-1119
LANGUAGE: English DOCUMENT TYPE: ARTICLE
ABSTRACT: A lectin-like substance (LS), that was isolated from Eikenella corrodens (Ec) 1073, migrated as proteins of about 300 and 45 kDa upon *sodium"** *dodecyl"** sulfate-*polyacrylamide"** gel *electrophoresis"** under reducing conditions. In this study, we cloned the gene encoding the 45-kDa protein and predicted its structure and function. Based on the N-terminal 23-amino acid (aa) sequence of this protein, we cloned the region for its N-terminus. We cloned the entire gene by means of gene walking using polymerase chain reaction and Southern hybridization. The *nucleotide"** sequences of cloned fragments revealed an open reading frame encoding a polypeptide of 330 aa (M(r) 35 748). This ORF displayed high homology to those of porins of Neisseria species. Using the T7-expression system, the 45-kDa protein was produced in E. coli. Our results suggested that the 45-kDa protein of Ec 1073 is a component of the EcLS complex, and that it is the major outer membrane protein.

4/3,AB/5 (Item 3 from file: 440)

06385894 GENUINE ARTICLE#: QW529 NUMBER OF REFERENCES: 53
TITLE: INTERACTION OF THE *NEISSERIA"** GONORRHOEAE PILA *PROTEIN"** WITH THE PILE PROMOTER INVOLVES MULTIPLE SITES ON THE *DNA"**
AUTHOR(S): ARVIDSON CG; SO M
CORPORATE SOURCE: OREGON HLTH SCI UNIV,DEPT MOLEC MICROBIOL & IMMUNOL,3181 SW SAM JACKSON PK RD/PORTLAND//OR/97201 (Reprint)
PUBLICATION: JOURNAL OF BACTERIOLOGY, 1995, V177, N9 (MAY), P2497-2504
ISSN: 0021-9193
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE
ABSTRACT: PilA is the putative *DNA"**-binding component of a two component system that regulates transcription of the pilin expression locus (pilE) of Neisseria gonorrhoeae. Here we report the purification of the PilA protein and characterization of its *DNA"**-binding activity. PilA was overproduced in Escherichia coli with an isopropyl-beta-D-thiogalactopyranoside (IPTG)-inducible expression vector. Cell extracts were prepared by sonication and fractionated by anion-exchange chromotography, followed by dye affinity chromatography with Cibacron Blue. Proteins were eluted by using a gradient of KCl, and PiLA-containing fractions were identified by immunoblot analysis with a polyclonal anti-PilA antiserum. Purified PilA was judged to be >90% pure, as determined by Coomassie blue staining and *sodium"** *dodecyl"** sulfate-*polyacrylamide"** gel *electrophoresis"**. PilA purified in this manner was used to develop a gel retardation assay with a 301-bp fragment containing the pilE promoter (P-pilE) and upstream sequences as a probe. A fragment of similar size containing the E. coli aroH promoter was used as a negative control. Competition

experiments using a 100- to 1,000-fold excess of unlabelled *DNA"** fragments confirmed the specificity of PilA binding to the pilE promoter. To localize the PilA binding site within the 301-bp P-pilE fragment, stepwise deletions were generated by PCR and the fragments were examined in the gel shift assay. The results of these experiments show that there are two regions upstream of P-pilE that are required for binding by PilA. Taken together, these data indicate that while PilA binds specifically to the upstream region of the pilE gene, this interaction is complex and likely involves multiple regions of this *DNA"** sequence.

4/3,AB/6 (Item 4 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

05278413 GENUINE ARTICLE#: MZ478 NUMBER OF REFERENCES: 29
TITLE: GENETIC DIVERSITY OF THE IRON-BINDING PROTEIN (FBP) GENE OF THE PATHOGENIC AND COMMENSAL NEISSERIA
AUTHOR(S): GENCO CA; BERISH SA; CHEN CY; MORSE S; TREES DL
CORPORATE SOURCE: MOREHOUSE SCH MED,DEPT MICROBIOL & IMMUNOL/ATLANTA//GA/30310 (Reprint); CTR DIS CONTROL,NATL CTR INFECT DIS,DIV SEXUALLY TRANSMITTED DIS LAB RES/ATLANTA//GA/30333
PUBLICATION: FEMS MICROBIOLOGY LETTERS, 1994, V116, N2 (FEB 15), P123-129
ISSN: 0378-1097
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE
ABSTRACT: The pathogenic Neisseria and most commensal *Neisseria"** species produce an iron-binding *protein"** (Fbp) when grown under iron-limited conditions. In the current study, we confirmed the presence of Fbp, as well as *DNA"** sequences homologous to the gonococcal fbp, in strains of N. gonorrhoeae, N. meningitidis, N. cinerea, N. lactamica, N.subflava, N.kochii and N. polysaccharea. The fbp genes from these strains were amplified by the polymerase chain reaction, digested with StuI or RsaI, and the restriction patterns examined. The patterns for the gonococcal and meningococcal fbp were virtually identical; however, variations were observed in the fbp sequences of the commensal Neisseria species. N. flavescens, N. mucosa, N. sicca, N. ovis and Branhamella catarrhalis, did not produce Fbp as detected by *sodium"** *dodecyl"** sulfate-*polyacrylamide"** gel *electrophoresis"** and reactivity with an Fbp specific monoclonal antibody, nor did they hybridize to an fbp-specific *DNA"** probe.

4/3,AB/7 (Item 5 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

04936019 GENUINE ARTICLE#: MB916 NUMBER OF REFERENCES: 44
TITLE: EXPRESSION OF MENINGOCOCCAL EPITOPES IN LAMB OF ESCHERICHIA-COLI AND

THE STIMULATION OF SEROSUBTYPE-SPECIFIC ANTIBODY RESPONSES
AUTHOR(S): MCCARVIL J; MCKENNA AJ; GRIEF C; HOY CS; SESARDIC D; MAIDEN MCJ; FEAVERS IM (Reprint)
CORPORATE SOURCE: NATL INST BIOL STAND & CONTROLS,DIV BACTERIOL,BLANCHE LANE/POTTERS BAR/HERTS EN6 3QG/ENGLAND/ (Reprint); NATL INST BIOL STAND & CONTROLS,DIV BACTERIOL,BLANCHE LANE/POTTERS BAR/HERTS EN6 3QG/ENGLAND/
PUBLICATION: MOLECULAR MICROBIOLOGY, 1993, V10, N1 (OCT), P203-213
ISSN: 0950-382X
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE
ABSTRACT: The class 1 outer membrane protein (OMP), a major variable surface antigen of Neisseria meningitidis, is a component of novel meningococcal vaccines currently in field trials. Serological variants of the protein are also used to serosubtype meningococci. Most of the amino acid changes that give rise to antigenic variants of the protein occur in two variable regions (VR1 and VR2) that are thought to form loops on the cell surface. The polymerase chain reaction (PCR) was used to amplify the *nucleotide"** sequences encoding VR1 and VR2 from the chromosomal *DNA"** of N. meningitidis strain M1080. These were cloned in frame into the lamB gene of the Escherichia coli expression vector pAJC264. Whole-cell enzyme-linked immunosorbent assays (ELISAs), using monoclonal antibodies, and *SDS"**-*PAGE"** confirmed that, upon induction, strains of E. coli carrying these constructs expressed hybrid LamB proteins containing the N. meningitidis surface loops. These strains were used to immunize rabbits and the resultant polyclonal antisera reacted specifically with the class 1 OMP of reference strain M1080 (P1.7). Immunogold labelling of meningococcal cells and whole-cell dot-blot analyses with these antisera showed that the variable epitopes were exposed on the cell surface and confirmed that this approach could be used to obtain serosubtype-specific antisera. The binding profiles of the antisera were determined from their reactions with overlapping synthetic peptides and their reactivity compared with that of relevant serosubtype-specific monoclonal antibodies. This approach was used successfully to raise antisera against two other class 1 OMP VR2s. A fourth antiserum raised against a VR2, including the P1.1 epitope, was not subtype specific.

04082819 GENUINE ARTICLE#: JU856 NUMBER OF REFERENCES: 29
TITLE: IDENTIFICATION OF MENINGOCOCCAL SEROSUBTYPES BY POLYMERASE CHAIN REACTION
AUTHOR(S): MAIDEN MCJ; BYGRAVES JA; MCCARVIL J; FEAVERS IM (Reprint)
CORPORATE SOURCE: NAT INST BIOL STAND & CONTROL/POTTERS BAR EN6 3QG/HERTS/ENGLAND/ (Reprint); NAT INST BIOL STAND & CONTROL/POTTERS BAR EN6 3QG/HERTS/ENGLAND/

PUBLICATION: JOURNAL OF CLINICAL MICROBIOLOGY, 1992, V30, N11 (NOV), P 2835-2841
ISSN: 0095-1137
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE
ABSTRACT: The polymerase chain reaction was used as the basis of a novel typing method for Neisseria meningitidis. Southern hybridization experiments demonstrated that it was possible to identify genes encoding different serological variants of the meningococcal class 1 outer membrane protein by probing with polymerase chain reaction products corresponding to known epitopes. A set of 14 defined variable regions was prepared in bacteriophage M13mp19 by the cloning of polymerase chain reaction products. The phage were dot blotted onto membrane filters, which were used as targets for hybridization of radiolabeled amplified class 1 outer membrane protein genes. Thus, the presence of many different subtype-specific epitopes could be investigated in one experiment. This technique was evaluated with a set of serological reference strains, mainly of serogroup B organisms, and provided an alternative, rapid, and comprehensive typing system that was capable of distinguishing known serosubtypes and also of defining currently untypeable strains independently of *sodium"** *dodecyl"** sulfate-*polyacrylamide"** gel *electrophoresis"** or serological analysis. An additional advantage of this technique was that in the case of an unknown serosubtype (i.e., one that did not hybridize with any of the known samples), the *DNA"** amplified from the original sample could be used to determine the *nucleotide"** sequence of the novel serosubtype and to clone the corresponding variable region into bacteriophage M13. It may be possible to develop this procedure for the diagnostic detection and typing of meningococci directly from clinical samples even when culture is not possible because of antibiotic treatment of an acute case.

4/3,AB/9 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01234610
Neisseria meningitidis compounds and anti-infection applications thereof
Neisseria meningitidis Zusammensetzungen und ihre Verwendungen als anti-infektionsmitteln
Compositions a base de Neisseria meningitidis et leur utilisation comme agents anti-infectieux
PATENT ASSIGNEE:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), (248490), 101, rue de Tolbiac, 75654 Paris Cedex 13, (FR), (Applicant designated States: all)
Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., (210792), Hofgartenstrasse 2, 80539 Munchen, (DE), (Applicant designated States: all)

INVENTOR:
Nassif, Xavier, 1, Square Charles Laurent, 75015 Paris, (FR)
Tinsley, Colin, 16 Square Jean Thebaud, 75015 Paris, (FR)
LEGAL REPRESENTATIVE:
Peaucelle, Chantal et al (17723), Cabinet Armengaud Aine 3, avenue Bugeaud, 75116 Paris, (FR)
PATENT (CC, No, Kind, Date): EP 1069133 A1 010117 (Basic)
APPLICATION (CC, No, Date): EP 99401764 990713;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C07K-014/22; C12N-015/31; C07K-016/12; C12N-015/10; A61K-039/095; G01N-033/53

ABSTRACT EP 1069133 A1
The invention provides novel *Neisseria"** meningitidis (Nm) *polypeptides"** and *polynucleotides"** which cover the Nm genetic diversity, and which correspond to polypeptide of Nm outer membrane and/or periplasma, and to methods for producing such Nm compounds. Also provided are anti-Nm infection, and particularly diagnostic, prophylactic and therapeutic uses thereof.
ABSTRACT WORD COUNT: 49
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200103	2904
SPEC A	(English)	200103	23204
Total word count - document A			26108
Total word count - document B			0
Total word count - documents A + B			26108

4/3,AB/10 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00958329
Production of gonorrheal PIB proteins and vaccines
Herstellung von Gonorrhoe-pIB-Proteinen und Impstoffen
Production de proteines gonorrheiques pIB et de vaccins
PATENT ASSIGNEE:
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, (751080), , Chapel Hill, North Carolina 27514, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Carbonetti, Nicholas H., 1102A East Franklin Street, Chapel Hill, NC

27514, (US)
Sparling, P. Frederick, 303 Weaver Road, Chapel Hill, NC 27514, (US)
LEGAL REPRESENTATIVE:
Warcoin, Jacques (19071), Cabinet Regimbeau, 26, avenue Kleber, 75116 Paris, (FR)
PATENT (CC, No, Kind, Date): EP 869133 A1 981007 (Basic)
APPLICATION (CC, No, Date): EP 98101882 881123;
PRIORITY (CC, No, Date): US 124727 871124; US 242758 880909
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 395706 (EP 899005409)
INTERNATIONAL PATENT CLASS: C07K-014/22;

ABSTRACT EP 869133 A1
The invention concerns a substantially purified nucleic acid molecule encoding a full length amino acid sequence of *Protein"** IB of *Neisseria"** gonorrhoea, a method for producing a full length PIB *protein"** of *Neisseria"** gonorrhoea comprising culturing a host cell containing a vector having a *DNA"** sequence encoding a full length PIB protein, a polypeptide composition produced by said method and its therapeutic use including as a vaccine.
ABSTRACT WORD COUNT: 68

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9841	368
SPEC A	(English)	9841	12508
Total word count - document A			12876
Total word count - document B			0
Total word count - documents A + B			12876

4/3,AB/11 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00874787
SYSTEM FOR THE EXPRESSION OF HETEROLOGOUS ANTIGENS AS FUSION PROTEINS
SYSTEM ZUR EXPRESSION VON HETEROLOGEN ANTIGENEN ALS FUSIONSPROTEINE
SYSTEME D'EXPRESSION D'ANTIGENES HETEROLOGUES EN TANT QUE PROTEINES DE FUSION
PATENT ASSIGNEE:
CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA, (1256832), Avenida 31 entre 158 y 190, Cubanacan Playa, Ciudad Habana 12100, (CU), (Proprietor designated states: all)
INVENTOR:
DUARTE CANO, Carlos Antonio Apartamento 12,, Avenida 31 No. 18307 Cubanacan, Playa, Ciudad Habana 12100, (CU)

GUILLEN NIETO, Gerardo Enrique Linea No. 6,, entre N y O, Piso 4 Vedado, Plaza de la Revoluciun, Ciudad Habana 10400, (CU)
ALVAREZ ACOSTA, Anabel, Apartamento 1, Calle 184 No. 3112, Playa Ciudad Habana 12100, (CU)
CARPIO MUNOZ, Emilio Luis, Edificio 12 plantas, Apartamento 507, Olivos 1 Sancti Spiritus 60100, (CU)
QUINTANA VAZQUEZ, Diogenes, Calle Indalecio Sobrado No. 71, Pinar del Rio 20100, (CU)
GOMEZ RODRIGUEZ, Carmen Elena, Calle Pasaje Molina No. 5 Guanabacoa, Ciudad Habana 11100, (CU)
SILVA RODRIGEZ, Ricardo de la Caridad, Avenida 15 No. 4209 Playa, Ciudad Habana 11300, (CU)
NAZABAL GALVEZ, Consuelo Avenida 51 No. 31, Playa, Ciudad Habana 11300, (CU)
LEAL ANGULO, Maria de Jesus, Calle 186 No. 3115 Playa, Ciudad Habana 12100, (CU)
MARTIN DUNN, Alejandro Miguel Apartamento 11B,, Calle 15 No. 9 Vedado Plaza de la Revoluciun, Ciudad Habana 10400, (CU)
LEGAL REPRESENTATIVE:
Smulders, Theodorus A.H.J., Ir. et al (21191), Vereenigde Postbus 87930, 2508 DH Den Haag, (NL)
PATENT (CC, No, Kind, Date): EP 816506 A1 980107 (Basic)
EP 816506 B1 010103
WO 9726359 970724
APPLICATION (CC, No, Date): EP 97901516 970117; WO 97CU1 970117
PRIORITY (CC, No, Date): CU 1096 960117
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/62; C12N-015/31; C12N-015/48; C07K-014/22; C07K-014/16; C07K-016/12; A61K-039/095; C12N-015/70; C12N-001/21; C12N-1:21

ABSTRACT EP 816506 A1

The present invention relates to biotechnology and genetic engineering, particularly the expression of heterologous proteins in microorganisms through their fusion, by applying the recombinant *DNA"** technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 aminoacids of the antigen P64k of Neisseria meningitidis B:4 :P1.15. In particular, use is made of a recombinant plasmid containing said sequence, under the control of the triptophane promotor of E. coli and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of *DNA"** fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the

development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.
ABSTRACT WORD COUNT: 197

LANGUAGE (Publication,Procedural,Application): English; English; Spanish
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200101	548
CLAIMS B	(German)	200101	514
CLAIMS B	(French)	200101	607
SPEC B	(English)	200101	6625
Total word count - document A			0
Total word count - document B			8294
Total word count - documents A + B			8294

4/3,AB/12 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00656876
GONOCOCCAL ANTI-IDIOTYPIC ANTIBODIES AND METHODS AND COMPOSITIONS USING THEM
Anti idiotypische Antikorper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ANTICORPS ANTI-IDIOTYPIQUES GONOCOCCIQUES ET PROCEDES ET COMPOSITIONS LES UTILISANT
PATENT ASSIGNEE:
Rice, Peter A., (3024480), 55 Norfolk Road, Chestnut Hill, MA 02167, (US), (Proprietor designated states: all)
Gulati, Sunita, (3024490), 14 Wheeler Street, Gloucester, MA 01930, (US), (Proprietor designated states: all)
McQuillen, Daniel P., (3024500), 9 Holland Terrace, Needham, MA 02192, (US), (Proprietor designated states: all)
INVENTOR:
Rice, Peter A., 55 Norfolk Road, Chestnut Hill, MA 02167, (US)
Gulati, Sunita, 14 Wheeler Street, Gloucester, MA 01930, (US)
McQuillen, Daniel P., 9 Holland Terrace, Needham, MA 02192, (US)
LEGAL REPRESENTATIVE:
VOSSIUS & PARTNER (100311), Postfach 86 07 67, 81634 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 695192 A1 960207 (Basic)
EP 695192 B1 010228
WO 9422479 941013
APPLICATION (CC, No, Date): EP 94912962 940406; WO 94US3794 940406
PRIORITY (CC, No, Date): US 43663 930406
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-039/395; C12P-021/08; C12N-005/12;

G01N-033/569
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200109	497
CLAIMS B	(German)	200109	479
CLAIMS B	(French)	200109	494
SPEC B	(English)	200109	16656
Total word count - document A			0
Total word count - document B			18126
Total word count - documents A + B			18126

4/3,AB/13 (Item 5 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00634124
Novel plasmid for production of CRM protein and diphtheria toxin.
Neues Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin.
Nouveau plasmide pour la production de la proteine CRM et de la toxine de la diphtherie.
PATENT ASSIGNEE:
AMERICAN CYANAMID COMPANY, (212592), One Cyanamid Plaza, Wayne New Jersey 07470, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)
INVENTOR:
Metcalf, Benjamin J., 2480 Elmwood Avenue, Rochester, New York 14618, (US)
LEGAL REPRESENTATIVE:
Wachtershauser, Gunter, Prof. Dr. (12711), Patentanwalt Tal 29, D-80331 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 616034 A2 940921 (Basic)
EP 616034 A3 961016
APPLICATION (CC, No, Date): EP 94101770 940207;
PRIORITY (CC, No, Date): US 27283 930305
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/77; C12N-015/87; C12N-015/31; C12N-001/21; C12N-001/21; C12R-001/16

ABSTRACT EP 616034 A3
The invention pertains to a novel method and plasmid system for producing abundant quantities of CRM197 protein, diphtheria toxin or other CRM proteins related to diphtheria toxin, as well as to microorganisms transformed with the novel plasmid. A particularly preferred *DNA"** plasmid, designated pPX 3511, that combines the gene

for CRM197 from the nontoxigenic betaphage and the plasmid pNG2-22 is described. The novel plasmid system is capable of transforming strains of Corynebacterium diphtheriae into strains which are capable of expressing high levels of the CRM197 protein without the use of multiple lysogens. The invention provides in elegant means for increasing protein production without having to manipulate the expression vector, such as by increasing the promoter strength, or removing the promoter from iron regulation. (see image in original document)
ABSTRACT WORD COUNT: 150

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF2	222
SPEC A	(English)	EPABF2	3485
Total word count - document A			3707
Total word count - document B			0
Total word count - documents A + B			3707

4/3,AB/14 (Item 6 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00536407
Pneumococcal polysaccharide conjugate vaccine
Imfpstoff, enthaltend ein Pneumokokkenpolysaccharid-Konjugat
Vaccin a base de conjugue de polysaccharide de pneumocoque
PATENT ASSIGNEE:
Merck & Co., Inc., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;PT;SE)
INVENTOR:
Kniskern, Peter J., 841 Patterson Drive, Lansdale, PA 19446, (US)
Ip, Charlotte C., 1665 Chadwyck Place, Blue Bell, PA 19422, (US)
Hagopian, Arpi, 771 Hartley Drive, Lansdale, PA 19446, (US)
Hennessey Jr., John P., 114 Fox Hollow Road, Dublin, PA 18917, (US)
Miller, William J., 232 Old Church Road, North Wales, PA 19454, (US)
Kubek, Dennis J., 76 Carolina Avenue, Salem, West Virginia 26426, (US)
Burke, Pamela D., 862 Yorktown Street, Landsdale, PA 19446, (US)
Marburg, Stephen, 50 Concord Avenue, Metuchen, NJ 08840, (US)
Tolman, Richard L., 29 Upper Warren Way, Warren, NJ 07059, (US)
LEGAL REPRESENTATIVE:
Thompson, John Dr. et al (62771), Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road, Harlow, Essex CM20 2QR, (GB)
PATENT (CC, No, Kind, Date): EP 497525 A2 920805 (Basic)
EP 497525 A3 930310
EP 497525 B1 980819
APPLICATION (CC, No, Date): EP 92300655 920127;
Searcher : Shears 308-4994

PRIORITY (CC, No, Date): US 646570 910128; US 807942 911219
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-039/385; A61K-039/09; A61K-039/095; A61K-039/295; A61K-039/02; A61K-047/48;

ABSTRACT EP 497525 A2
A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.
ABSTRACT WORD COUNT: 105

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9834	1182
CLAIMS B	(German)	9834	1225
CLAIMS B	(French)	9834	1373
SPEC B	(English)	9834	25880
Total word count - document A			0
Total word count - document B			29660
Total word count - documents A + B			29660

4/3,AB/15 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00536406
Polysaccharide antigens from streptococcus pneumoniae
Polysaccharidantigene aus Streptococcus pneumoniae
Antigenes polysaccharadiques a partir de Streptococcus pneumoniae
PATENT ASSIGNEE:
Merck & Co., Inc., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;PT;SE)
INVENTOR:
Kniskern, Peter J., 841 Patterson Drive, Lansdale, PA 19446, (US)
Ip, Charlotte C., 1665 Chadwyck Place, Blue Bell, PA 19422, (US)
Hagopian, Arpi, 771 Hartley Drive, Lansdale, PA 19446, (US)

Hennessey Jr. John P., 114 Fox Hollow Road, Dublin, PA 18917, (US)
Miller, William J., 232 Old Church Road, North Wales, PA 19454, (US)
Kubek, Dennis J., 76 Carolina Avenue, Salem, West Virginia 26426, (US)
Burke, Pamela D., 862 Yorktown Street, Lansdale, PA 19446, (US)
LEGAL REPRESENTATIVE:
Thompson, John Dr. (62771), Merck & Co., Inc. European Patent Department
Terlings Park Eastwick Road, Harlow, Essex CM20 2QR, (GB)
PATENT (CC, No, Kind, Date): EP 497524 A2 920805 (Basic)
EP 497524 A3 930310
EP 497524 B1 980715
APPLICATION (CC, No, Date): EP 92300654 920127;
PRIORITY (CC, No, Date): US 646573 910128; US 807941 911219
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-039/09; C12P-019/04; C08B-037/00;

ABSTRACT EP 497524 A2
Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1.0 and 1.4, intrinsic viscosities between 0.6 and 3.0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.
ABSTRACT WORD COUNT: 98

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9829	831
CLAIMS B	(German)	9829	845
CLAIMS B	(French)	9829	963
SPEC B	(English)	9829	22499
Total word count - document A			0
Total word count - document B			25138
Total word count - documents A + B			25138

00533711
Conjugates of the class II *protein"** of the outer membrane of *neisseria"** meningitidis and of HIV-1 related peptides.

Konjugate des Klasse-II-*Proteins"** der ausseren Membran von *Neisseria"** Meningitidis mit HIV-1-verwandten *Peptiden"**.
Conjugues de la proteine classe II de la membrane exterieure de *neisseria"** meningitidis et de *peptides"** associes a HIV-1.

PATENT ASSIGNEE:
MERCK & CO. INC., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: CH;DE;FR;GB;IT;LI;NL)
INVENTOR:
Emini, A., 6 Faggs Manor Lane, Paoli, PA 19301, (US)
Liu, Margaret A., 4 Cushman Road, Rosemont, PA 19190, (US)
Marburg, Stephen, 50 Concord Avenue, Metuchen, NJ 08840, (US)
Tolman, Richard L., 29 Upper Warren Way, Warren, NJ 07059, (US)
LEGAL REPRESENTATIVE:
Thompson, John Dr. et al (62771), Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road, Harlow, Essex CM20 2QR, (GB)
PATENT (CC, No, Kind, Date): EP 519554 A1 921223 (Basic)
APPLICATION (CC, No, Date): EP 92201693 920611;
PRIORITY (CC, No, Date): US 715273 910619
DESIGNATED STATES: CH; DE; FR; GB; IT; LI; NL
INTERNATIONAL PATENT CLASS: C07K-017/06; C07K-003/28; A61K-039/385; A61K-039/21;

ABSTRACT EP 519554 A1
The Class II major immuno-enhancing *protein"** (MIEP) of *Neisseria"** meningitidis, purified directly from the outer membrane of Neisseria meningitidis, or obtained through recombinant cloning and expression of *DNA"** encoding the MIEP of Neisseria meningitidis, has immunologic carrier as well as immunologic enhancement and mitogenic properties. Conjugates of this protein and HIV-1 related peptides are useful for the induction of mammalian immune responses directed against the peptides, against HIV-1 strains, and for the neutralization of HIV-1 and prevention of HIV-I related diseases.
ABSTRACT WORD COUNT: 83

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1279
SPEC A	(English)	EPABF1	17403
Total word count - document A			18682
Total word count - document B			0
Total word count - documents A + B			18682

4/3,AB/17 (Item 9 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00510017
IMMUNOGENIC COMPLEXES, IN PARTICULAR ISCOMS.
IMMUNOGENE KOMPLEXE, INSBESONDERE ISCOMS.
COMPLEXES IMMUNOGENES, NOTAMMENT DES ISCOMES.
PATENT ASSIGNEE:
DE STAAT DER NEDERLANDEN VERTEGENWOORDIGD DOOR DE MINISTER VAN WELZIJN, VOLKSGEZONDHEID EN CULTUUR, (488602), P.O. Box 5406, NL-2280 HK Rijswijk, (NL), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
KERSTEN, Gideon, Frank, Anne, Zeelstraat 21, NL-3525 TC Utrecht, (NL)
SPIEKSTRA, Arjen, Zwaardenburg 48, NL-3437 RP Nieuwegein, (NL)
VAN DE WERKEN, Gerrit, Oldambt 11, NL-3524 BD Utrecht, (NL)
BEUVERY, Eduard, Coen, Kerkstraat 66, NL-4132 BG Vianen, (NL)
LEGAL REPRESENTATIVE:
de Bruijn, Leendert C. et al (19641), Nederlandsch Octrooibureau Scheveningseweg 82 P.O. Box 29720, NL-2502 LS Den Haag, (NL)
PATENT (CC, No, Kind, Date): EP 555276 A1 930818 (Basic)
EP 555276 B1 950830
WO 9206710 920430
APPLICATION (CC, No, Date): EP 91918619 911023; WO 91NL211 911023
PRIORITY (CC, No, Date): NL 902314 901023
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/39; C07H-015/256; A61K-039/385;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; Dutch
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB95	965
CLAIMS B	(German)	EPAB95	907
CLAIMS B	(French)	EPAB95	961
SPEC B	(English)	EPAB95	5823
Total word count - document A			0
Total word count - document B			8656
Total word count - documents A + B			8656

4/3,AB/18 (Item 10 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00508713
ADHESION RECEPTORS FOR PATHOGENIC OR OPPORTUNISTIC MICROORGANISMS
ADHASIONSREZEPTOREN FUR PATHOGENE ODER OPPORTUNISTISCHE MIKROORGANISMEN
RECEPTEURS D'ADHESION POUR DES MICRO-ORGANISMES PATHOGENES OU OPPORTUNISTES
PATENT ASSIGNEE:
Antex Biologics, Inc., (1525991), 300 Professional Drive, Gaithersburg, MD 20879, (US), (applicant designated states:

AT;CH;DE;DK;ES;FR;GB;IT;LI;NL;SE)
INVENTOR:
KRIVAN, Howard, C. Gregory Zakarian MicroCarb Inc., 300 Professional Drive, Suite 100, Gaithersburg, Maryland 20879, (US)
SAMUEL, James, E. c/o Greg. Zakarian MicroCarb Inc, 300 Professional Drive, Suite 100, Gaithersburg , Maryland 20879, (US)
LEGAL REPRESENTATIVE:
Berger, Helmut et al (49881), Cabinet WEINSTEIN 20, avenue de Friedland, 75008 Paris, (FR)
PATENT (CC, No, Kind, Date): EP 553113 A1 930804 (Basic)
EP 553113 A1 940330
EP 553113 B1 981125
WO 9202817 920220
APPLICATION (CC, No, Date): EP 91916508 910729; WO 91US5179 910729
PRIORITY (CC, No, Date): US 562002 900802
DESIGNATED STATES: AT; CH; DE; DK; ES; FR; GB; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS: G01N-033/53; C12P-021/00; G01N-033/569; G01N-033/566;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9848	1805
CLAIMS B	(German)	9848	1862
CLAIMS B	(French)	9848	1980
SPEC B	(English)	9848	10741
Total word count - document A			0
Total word count - document B			16388
Total word count - documents A + B			16388

4/3,AB/19 (Item 11 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00485895
The class II *protein"** of the outer membrane of *neisseria"** meningitidis.
Klasse-II-*Protein"** der ausseren Membran von *Neisseria"** meningitidis und dasselbe enthaltende Impfstoffe.
Classe II de la membrane exterieure de Neisseria meningitidis et raccins la contenant.
PATENT ASSIGNEE:
MERCK & CO. INC., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Oliff, Allen I., 1412 Florence Drive, Gwynedd Valley, PA 19437, (US)

Liu, Margaret A., 4 Cushman Road, Rosemont, PA 19190, (US)
Friedman, Arther, 121 Froghollow Road, Churchville, PA 18966, (US)
Tai, Joseph Y., 1370 Cinnamon Drive, Fort Washington, PA 19034, (US)
Donnelly, John J., 1505 Briarwood Road, Havertown, PA 19083, (US)
Jones, Deborah D., 1126 Canterbury Drive, Lansdale, PA 19446, (US)
Montgomery, Donna L., 9 Hickory Lane, Chalfont, PA 18914, (US)
Lowe, Robert S., 232 Maple Avenue, Harleysville, PA 19438, (US)
LEGAL REPRESENTATIVE:
Barrett-Major, Julie Diane et al (50911), Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road, Harlow Essex CM20 2QR, (GB)
PATENT (CC, No, Kind, Date): EP 467714 A1 920122 (Basic)
APPLICATION (CC, No, Date): EP 91306618 910719;
PRIORITY (CC, No, Date): US 555329 900719; US 555204 900719; US 555978 900719; US 639457 910110; US 715274 910619
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C07K-013/00; C07K-003/28; C12N-015/09; A61K-039/39; A61K-039/095;

ABSTRACT EP 467714 A1
The Class II major immuno-enhancing *protein"** (MIEP) of *Neisseria"** meningitidis, purified directly from the outer membrane of Neisseria meningitidis, or obtained through recombinant cloning and expression of *DNA"** encoding the MIEP of Neisseria meningitidis, has immunologic carrier as well as immunologic enhancement and mitogenic properties.
ABSTRACT WORD COUNT: 47

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1309
SPEC A	(English)	EPABF1	25077
Total word count - document A			26386
Total word count - document B			0
Total word count - documents A + B			26386

4/3,AB/20 (Item 12 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00446976
A METHOD FOR ISOLATING AND PURIFYING TRANSFERRIN AND LACTOFERRIN RECEPTOR PROTEINS FROM BACTERIA AND THE PREPARATION OF VACCINES CONTAINING THE SAME
VERFAHREN ZUR ISOLIERUNG UND REINIGUNG VON REZEPTOREN FUR TRANSFERRIN UND LACTOFERRIN VON BAKTERIEN UND HERSTELLUNG VON IMPFSTOFFEN, DIE SIE ENTHALTEN
PROCEDE PERMETTANT D'ISOLER ET DE PURIFIER DES PROTEINES RECEPTRICES DE

TRANSFERRINE ET DE LACTOFERRINE A PARTIR DE BACTERIES ET PREPARATION DE VACCINS CONTENAN
PATENT ASSIGNEE:
UNIVERSITY TECHNOLOGIES INTERNATIONAL INC., (1298540), ES620, 2500 University Drive, N.W., Galgary, Alberta T2N 1N4, (CA), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)
SCHRYVERS, Anthony Bernard, (1438060), 39 Edforth Road, N.W., Calgary, Alberta T3A 3A3, (CA), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
SCHRYVERS, Anthony, Bernard, 39 Edforth Road, N.W., Calgary, Alberta T3A 3A3, (CA)
LEGAL REPRESENTATIVE:
Bernasconi, Jean et al (13921), c/o Cabinet Lavoix, 2, Place d'Estienne d'Orves, 75441 Paris Cedex, (FR)
PATENT (CC, No, Kind, Date): EP 528787 A1 930303 (Basic)
EP 528787 B1 981202
WO 9012591 901101
APPLICATION (CC, No, Date): EP 90906093 900426; WO 90CA131 900426
PRIORITY (CC, No, Date): US 344356 890427; US 507481 900411
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/095; A61K-039/102; A61K-039/02;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9849	871
CLAIMS B	(German)	9849	845
CLAIMS B	(French)	9849	998
SPEC B	(English)	9849	6500
Total word count - document A			0
Total word count - document B			9214
Total word count - documents A + B			9214

4/3,AB/21 (Item 13 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00443912
MENINGOCOCCAL CLASS 1 OUTER-MEMBRANE PROTEIN VACCINE.
MENINGOCOCCALES KLASSE I-AUSSENMEMBRANPROTEIN-VAKZIN.
VACCIN MENINGOCOQUE DE LA PROTEINE DE LA MEMBRANE EXTERNE DE LA CLASSE 1.
PATENT ASSIGNEE:
PRAXIS BIOLOGICS, INC., (693522), 30 Corporate Woods, Rochester NY 14623-1493, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;IT;LI;LU;NL;SE)
De Staat der Nederlanden, represented by the Deputy Director-General of

the RIVM of Bilthoven, (935230), Antonie van Leeuwenhoeklaan 9, NL-3720 BA Bilthoven, (NL), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:
SEID, Robert, C., Jr., 590 25th Avenue, San Francisco, CA 94121, (US)
PARADISO, Peter, R., 6 Guilford Way, Pittsford, NY 14534, (US)
POOLMAN, Jan, T., Leeteinde 8, NL-1151 AK Broek in Waterland, (NL)
HOOGERHOUT, Peter, Idenburgstraat 13, NL-2805 SZ Gouda, (NL)
WIERTZ, Emmanuel, J., H., J., Mauritsstraat 106, NL-3583 HW Utrecht, (NL)
VAN DER LEY, Peter, Adriaan van Ostadelaan 124, NL-3583 AM Utrecht, (NL)
HECKELS, John, Edward 6 Arun Way West Wellow, Romsey, Hampshire SO51 6GT, (GB)
CLARKE, Ian, Nicholas 15 Fernyhurst Avenue, Rownhams Southampton, Hampshire SO1 8DR, (GB)

LEGAL REPRESENTATIVE:
Roques, Sarah Elizabeth et al (79543), J.A. Kemp & Co. 14 South Square Gray's Inn, London WC1R 5LX, (GB)

PATENT (CC, No, Kind, Date): EP 449958 A1 911009 (Basic)
EP 449958 B1 950322
WO 9006696 900628

APPLICATION (CC, No, Date): EP 90901397 891219; WO 89US5678 891219

PRIORITY (CC, No, Date): NL 883111 881219; NL 8936 890106; NL 891612 890626

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/095; C07K-014/22; C07K-007/04; A61K-039/39; A61K-039/385; C12N-015/31; C12N-015/62; C12N-015/31; C12R-001/36

NOTE:
No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB95	2262
CLAIMS B	(German)	EPAB95	2235
CLAIMS B	(French)	EPAB95	2904
SPEC B	(English)	EPAB95	14719
Total word count - document A			0
Total word count - document B			22120
Total word count - documents A + B			22120

4/3,AB/22 (Item 14 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00381394
PRODUCTION OF GONORRHEAL PI PROTEINS AND VACCINES
HERSTELLUNG DER P1 PROTEINE UND IMPFSTOFFE GEGEN GONORRHOE
PRODUCTION DE PROTEINES PI ET DE VACCINS GONORRHEIQUES
PATENT ASSIGNEE:

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, (751080), , Chapel Hill, North Carolina 27514, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
CARBONETTI, Nicholas, H., Via Colombini 9, 53100 SIENA, (IT)
SPARLING, P., Frederick, Route 1, Box 980, MONTCURE, NC 27559, (US)
LEGAL REPRESENTATIVE:
Martin, Jean-Jacques et al (17181), Cabinet REGIMBEAU 26, Avenue Kleber, 75116 Paris, (FR)
PATENT (CC, No, Kind, Date): EP 395706 A1 901107 (Basic)
EP 395706 A1 911113
EP 395706 B1 980819
WO 8904873 890601
APPLICATION (CC, No, Date): EP 89900540 881123; WO 88US4225 881123
PRIORITY (CC, No, Date): US 124727 871124; US 242758 880909
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C12N-015/31; C07K-014/22; A61K-039/00;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9834	524
CLAIMS B	(German)	9834	561
CLAIMS B	(French)	9834	583
SPEC B	(English)	9834	12132
Total word count - document A			0
Total word count - document B			13800
Total word count - documents A + B			13800

4/3,AB/23 (Item 15 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00345951
Neisserial vaccines.
Neisseria-Vakzine.
Vaccins contre Neisseria.
PATENT ASSIGNEE:
THE ROCKEFELLER UNIVERSITY, (315600), 1230 York Avenue, New York, NY 10021, (US), (applicant designated states: BE;CH;DE;FR;GB;IT;LI;NL;SE)
INVENTOR:
Gotschlich, Emil Claus, 500 East 63rd Street, New York, NY 10021, (US)
Blake, Milan Scott, 500 East 63rd Street, New York, NY 10021, (US)
Wetzler, Lee Mark, 500 East 63rd Street, New York, NY 10021, (US)
Koomey, John Michael, 238 East 81st Street, New York, NY 10028, (US)
LEGAL REPRESENTATIVE:
VOSSIUS & PARTNER (100311), Postfach 86 07 67, D-81634 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 351604 A1 900124 (Basic)
EP 351604 B1 940914
APPLICATION (CC, No, Date): EP 89111832 890629;
PRIORITY (CC, No, Date): US 212786 880629
DESIGNATED STATES: BE; CH; DE; FR; GB; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS: C12N-015/31; A61K-039/095;
ABSTRACT EP 351604 A1

This invention relates to mutants of Neisseria useful for vaccine preparation. Specifically this invention relates to mutants of Neisseria containing mutations in a major outer membrane protein gene such that no immunologically functional polypeptides encoded by said gene are produced. More specifically, the invention relates to a mutant strain of Neisseria gonorrhoeae or Neisseria meningitidis having a mutation of the PIII gene or Class 4 gene respectively and to vaccines derived therefrom.

ABSTRACT WORD COUNT: 76

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF1	638
CLAIMS B	(English)	EPBBF1	475
CLAIMS B	(German)	EPBBF1	444
CLAIMS B	(French)	EPBBF1	537
SPEC A	(English)	EPBBF1	7615
SPEC B	(English)	EPBBF1	7889
Total word count - document A			8253
Total word count - document B			9345
Total word count - documents A + B			17598

4/3,AB/24 (Item 16 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00309966
Vaccine against pasteurella
Impfstoff gegen Pasteurella
Vaccin contre pasteurella
PATENT ASSIGNEE:
BTG INTERNATIONAL LIMITED (Company No. 2664412), (1475433), 10 Fleet Place Limeburner Lane, London EC4M 7SB, (GB), (Proprietor designated states: all)
INVENTOR:
Donachie, William, 7 Beechbank Crescent, East Calder, West Lothian, EH53 0DX, (GB)
LEGAL REPRESENTATIVE:
Percy, Richard Keith et al (46441), Patents Department British Technology Group Ltd 10 Fleet Place, London EC4M 7SB, (GB)

PATENT (CC, No, Kind, Date): EP 287206 A1 881019 (Basic)
EP 287206 B1 930804
EP 287206 B2 991124
APPLICATION (CC, No, Date): EP 88301932 880304;
PRIORITY (CC, No, Date): GB 8706944 870324; GB 8721286 870910
DESIGNATED STATES: BE; DE; ES; FR; IT; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/02; C12N-001/38; C12P-021/00; C07K-001/00; C07K-001/14

ABSTRACT EP 287206 A1
A vaccine against pasteurellosis is obtained from Pasteurella grown under iron restriction conditions.
ABSTRACT WORD COUNT: 17

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9947	900
CLAIMS B	(German)	9947	934
CLAIMS B	(French)	9947	1005
SPEC B	(English)	9947	6261
Total word count - document A			0
Total word count - document B			9100
Total word count - documents A + B			9100

4/3,AB/25 (Item 17 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00248198
Filamentous fungal expression systems.
Expressionsysteme in fadenformigen Pilzen.
Systemes d'expression de champignons filamenteux.
PATENT ASSIGNEE:
PANLABS, INC., (807040), 9725 Third Avenue, N.E., Seattle, WA 98115, (US)
, (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Finkelstein, David B., 5535 56th Avenue S., Seattle Washington 98118, (US)
Leach, Janette, 1401 5th Avenue, Seattle Washington 98115, (US)
McAda, Phyllis C., 9226 15th Avenue NE, Seattle Washington 98115, (US)
Rambosek, John A., 8923 Ravenna Avenue NE, Seattle Washington 98115, (US)
Soliday, Charles L., 14235 209 Avenue NE, Woodinville Washington 98072, (US)
LEGAL REPRESENTATIVE:
Harrison, David Christopher et al , MEWBURN ELLIS & CO 2/3 Cursitor Street, London EC4A 1BQ, (GB)
PATENT (CC, No, Kind, Date): EP 249350 A1 871216 (Basic)

APPLICATION (CC, No, Date): EP 87304477 870520;
PRIORITY (CC, No, Date): US 871532 860606
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C12N-015/00; C07H-021/04; C12N-005/00; C12N-005/00; C12R-001/66

ABSTRACT EP 249350 A1
Novel expression constructs for secretion of protein products in filamentous fungal hosts are provided. The hosts are transformed with the constructs, normally under conditions for multiple integration of the constructs into the host genome, where the desired protein products are expressed and secreted from the host to provide for enhanced yields of the product, substantially free of host proteins. Efficient filamentous fungal promoters are employed which may be from the same or different gene from the signal leader sequence.
ABSTRACT WORD COUNT: 83

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	388
SPEC A	(English)	EPABF1	6808
Total word count - document A			7196
Total word count - document B			0
Total word count - documents A + B			7196

4/3,AB/26 (Item 18 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00233369
ORAL VACCINES
ORALE IMPFSTOFFE
VACCINS ORAUX
PATENT ASSIGNEE:
BIOTECHNOLOGY AUSTRALIA PTY. LTD., (374170), 28 Barcoo Street, East Roseville, NSW 2069, (AU), (Proprietor designated states: all)
INVENTOR:
RUSSELL-JONES, Gregory, John, 101/2 Artarmon Road, Willoughby, NSW 2068, (AU)
DE AIZPURUA, Henry, James, 9 Douglas Street, Bexley, NSW 2207, (AU)
HOWE, Peter, 6 Mundon Place, West Pennant Hills, NSW 2120, (AU)
RAND, Keith, Norman, 10A Ferncourt Avenue, Chatswood, NSW 2067, (AU)
LEGAL REPRESENTATIVE:
Adkins, Michael et al (42842), Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW, (GB)
PATENT (CC, No, Kind, Date): EP 222835 A1 870527 (Basic)
EP 222835 A1 880323

EP 222835 B1 940928
EP 222835 B2 000419
WO 8606635 861120
APPLICATION (CC, No, Date): EP 86903134 860514; WO 86AU135 860514
PRIORITY (CC, No, Date): AU 85566 850515; AU 853104 851025
DESIGNATED STATES: BE; CH; DE; FR; GB; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/385; C07K-017/00; C12N-001/20; C12N-015/00
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200016	1870
CLAIMS B	(German)	200016	1774
CLAIMS B	(French)	200016	2210
SPEC B	(English)	200016	8788
Total word count - document A			0
Total word count - document B			14642
Total word count - documents A + B			14642

4/3,AB/27 (Item 19 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00189516
Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents.
Immunogenischer Komplex, Verfahren zu seiner Herstellung und Verwendung desselben als Immunostimulans, Impfstoffe und Reagenzien.
Complexe immunogenique, procede de preparation et son utilisation comme immunostimulant, vaccins et reactifs.
PATENT ASSIGNEE:
Morein, Bror, (712050), Ollonstigen 3 Vreta, S-75590 Uppsala, (SE), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Morein, Bror, Ollonstigen 3 Vreta, S-75590 Uppsala, (SE)
LEGAL REPRESENTATIVE:
Fagerlin, Helene et al (22771), H. ALBIHNS PATENTBYRA AB P.O. Box 3137, S-103 62 Stockholm, (SE)
PATENT (CC, No, Kind, Date): EP 180564 A2 860507 (Basic)
EP 180564 A3 880601
EP 180564 B1 910717
APPLICATION (CC, No, Date): EP 85850326 851016;
PRIORITY (CC, No, Date): SE 845493 841101
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/385; A61K-039/44; A61K-039/39; A61K-045/05;

ABSTRACT EP 180564 A2

Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents.

The invention relates to a process for preparing an immunogenic complex comprising a carrier molecule prepared by mixing viruses, mycoplasmas, bacterias, animal cells or proteins or peptides having hydrophobic regions with one or more solubilizing agents, whereby a complex having been formed between proteins or peptides and solubilizing agents, whereafter the proteins or the peptides have been separated from the solubilizing agent in the presence of a glycoside solution which contains one or more glycosides having hydrophobic and hydrophilic regions in a concentration of at least the critical micellular concentration, or alternatively have been separated from the solubilizing agent and transferred directly to the aforementioned glycoside solution, and the carrier molecule being bound to one or more molecules selected from peptides, proteins, carbohydrates, lipoproteins, glycolipides or small molecules, such as biotine, by coupling with known methods between functional coupling groups in the bound molecules and functional groups in the peptides or the proteins in the carrier molecule.

The invention also relates to a method for preparing such immunogenic complexes, compositions, vaccines containing such complexes and to reagents.

ABSTRACT WORD COUNT: 198

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	2040
CLAIMS B	(German)	EPBBF1	1976
CLAIMS B	(French)	EPBBF1	2409
SPEC B	(English)	EPBBF1	14046
Total word count - document A			0
Total word count - document B			20471
Total word count - documents A + B			20471

4/3,AB/28 (Item 20 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

00187286

Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing suc

Kovalentlich modifizierte neutrale bakterielle Polysaccharide, stabile kovalente Konjugate zwischen diesen Polysacchariden und immunogenischen Proteinen und Ver

Polysaccharides bacteriens neutres modifies de maniere covalente, conjuges

stables covalents entre ces polysaccharides et des proteines immunogeniques et method

PATENT ASSIGNEE:
MERCK & CO. INC., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:
Marburg, Stephen, 50 Concord Avenue, Metuchen New Jersey 08840, (US)
Tolman, Richard L., 29 Upper Warren Way, Warren New Jersey 07060, (US)
Jorn, Deborah A., 27 Ticonderoga Blvd, Freehold New Jersey 07728, (US)

LEGAL REPRESENTATIVE:
Warcoin, Jacques et al (19071), Cabinet Regimbeau 26, avenue Kleber, F-75116 Paris, (FR)

PATENT (CC, No, Kind, Date): EP 186576 A2 860702 (Basic)
EP 186576 A3 890125
EP 186576 B1 920722

APPLICATION (CC, No, Date): EP 85402472 851212;
PRIORITY (CC, No, Date): US 684401 841220
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C07K-017/10; A61K-039/02; A61K-039/40; A61K-039/116;

ABSTRACT EP 186576 A2
Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates.
Covalently-modified neutral bacterial polysaccharides; covalent conjugates of such polysaccharides linked by a bigeneric spacer, with immunogenic bacterial membrane or other proteins, which conjugates are useful components of bacterial vaccines; and methods of preparing such polysaccharides and conjugates.
ABSTRACT WORD COUNT: 60

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1090
CLAIMS B	(German)	EPBBF1	1061
CLAIMS B	(French)	EPBBF1	1274
SPEC B	(English)	EPBBF1	8704
Total word count - document A			0
Total word count - document B			12129
Total word count - documents A + B			12129

4/3,AB/29 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs

0252760 DBA Accession No.: 2000-07250 PATENT
*Neisseria"** meningitidis NMASP *polypeptide"**, *nucleotide"** sequences and antibodies, useful in vaccines against infection - method is used to induce an immune response to *Neisseria"** meningitidis and *Neisseria"** meningitidis NMASP *polypeptide"** and a NMASP-derived polypeptide in animals
AUTHOR: Jackson W J; Harris A M
CORPORATE SOURCE: Gaithersburg, MD, USA
PATENT ASSIGNEE: Antex-Biologics 2000
PATENT NUMBER: WO 200012535 PATENT DATE: 20000309 WPI ACCESSION NO.: 2000-256581 (2022)
PRIORITY APPLIC. NO.: US 98685 APPLIC. DATE: 19980901
NATIONAL APPLIC. NO.: WO 99US19663 APPLIC. DATE: 19990901
LANGUAGE: English
ABSTRACT: *Neisseria"** meningitidis NMASP *protein"** of mol.wt. 40,000-55,000 (*SDS"**-*PAGE"**) is claimed. Also claimed are: a peptide fragment of NMASP; an isolated antibody that binds NMASP; an antigenic composition (comprises one or more adjuvants) comprising NMASP; an isolated *DNA"** comprising a *nucleotide"** sequence encoding NMASP; an isolated *DNA"** sequence having a 153 base pair sequence; an isolated *DNA"** which comprises a *nucleotide"** sequence that hybridizes to a disclosed sequence; plasmid pNmAH116 obtainable from Escherichia coli; a method (A) for assaying for an agent that interacts with NMASP; an antagonist which inhibits the activity of NMASP; and a method for identifying a compound which interacts with and inhibitor or activate of NMASP. NMASP can be used in a method to produce an immune response in an animal. The sequence and antibody are useful for protection against N. meningitidis, also may be used as ligands to detect antibodies elicited in response to N. meningitidis infection. Antibody generated against the NMASP polypeptide in an animal host will exhibit bactericidal or opsonic activity against many N. meningitidis strains. (75pp)

4/3,AB/30 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs

0131273 DBA Accession No.: 92-03765 PATENT
Purified class-II outer membrane *protein"** of *Neisseria"** meningitidis - major immunoenhancing protein gene cloning and expression in yeast or bacterium; use as adjuvant e.g. in recombinant vaccine production
PATENT ASSIGNEE: Merck-USA 1992
PATENT NUMBER: EP 467714 PATENT DATE: 920122 WPI ACCESSION NO.: 92-026518 (9204)
PRIORITY APPLIC. NO.: US 715274 APPLIC. DATE: 910619
NATIONAL APPLIC. NO.: EP 91306618 APPLIC. DATE: 910719
LANGUAGE: English
ABSTRACT: A new purified Gram-negative bacterium outer membrane protein

(major immunoenhancing protein) shows immunostimulant and mitogenic activity in mammals, particularly adult and infant humans. The *protein"** is preferably *Neisseria"** meningitidis serogroup B class-II *protein"**, and may be produced recombinantly in a yeast or bacterium host. The protein may be used as an adjuvant when coupled to an antigen (e.g. a bacterium, virus, mammal cell, fungus or Rickettsia antigen, or an allergen, toxin, venom, synthetic peptide or polypeptide) in a conjugate or recombinant vaccine (e.g. a polysaccharide-protein conjugate of Haemophilus influenzae serotype B polysaccharide and the new protein), or for increasing interleukin-2 levels. The native protein may be purified by lysis of the outer membrane with *SDS"**, *SDS"**-*PAGE"**, elution, dialysis against high pH buffer and concentration. The recombinant protein may be produced by extracting genomic *DNA"** from N. meningitidis, inserting into a cloning vector or amplifying by the polymerase chain reaction, expression in a host, and purification by affinity chromatography. (73pp)

4/3,AB/31 (Item 3 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs

0106050 DBA Accession No.: 90-08741
Stable expression of meningococcal class 1 protein in an antigenically reactive form in outer membranes of Escherichia coli - *Neisseria"** meningitidis outer membrane *protein"** class 1 gene cloning and expression in Escherichia coli; potential application in recombinant vaccine development
AUTHOR: White D A; Barlow A K; Clarke I N; +Heckles J E
CORPORATE SOURCE: Department of Microbiology, University of Southampton Medical School, Southampton General Hospital, Southampton SO9 4XT, UK.
JOURNAL: Mol.Microbiol. (4, 5, 769-76) 1990
CODEN: MOMIEE
LANGUAGE: English
ABSTRACT: Neisseria meningitidis MC50 chromosomal *DNA"** was digested with XbaI to give a 2.2 kb fragment containing the structural gene of the class 1 outer membrane protein. The XbaI fragment was cloned into vector plasmid pMTL20 and the resultant plasmid pPORA100 was transformed into Escherichia coli JM1090. *SDS"**-*PAGE"** and Western blotting of cell lysates revealed constitutive expression of a protein of mol.wt. 41,000, corresponding to the class 1 protein of the parent meningococcal strain. The recombinant membrane protein was exclusively located in the outer membrane of transformed E. coli. N-terminal analysis indicated that normal processing of the signal peptide had occurred. Immuno-gold EM indicated that the protective epitope recognized by a P1-16 subtype-specific monoclonal antibody was present in an antigenically reactive form on the surface of transformed E. coli. In the absence of amino acids 1-15 of the signal peptide,

recombinant class 1 protein accumulated in the cytoplasm. These constructs may have potential applications in the development of effective recombinant vaccines against meningococcal infection in humans. (42 ref)

4/3,AB/32 (Item 4 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs

0091983 DBA Accession No.: 89-09974
Analysis of sequence variation and conservation of pilin and other *proteins"** among strains of *Neisseria"** gonorrhoeae using polymerase chain reaction - *DNA"** amplification (conference abstract)
AUTHOR: Ryan G; Loriaux M; Deal C D
CORPORATE SOURCE: Walter Reed Army Institute of Research, Washington, DC, USA.
JOURNAL: Abstr.Annu.Meet.Am.Soc.Microbiol. (89 Meet., 123) 1989
CODEN: 0005M
LANGUAGE: English
ABSTRACT: Antigenic variation of pilin is well known in gonococcus. Polymerase chain reaction (PCR) techniques were adapted to the amplification of pilus-specific message in order to accumulate a wide gene bank of pilin sequences for comparison of variant and constant regions. A reverse transcription reaction, followed by 30 rounds of amplification, resulted in *DNA"** which could be directly sequenced. *SDS"**-*PAGE"** of pilus preparations revealed several proteins which co-purify with pilin. Analogy to other bacteria suggested that pilus-associated proteins may play a role in bacterial adherence. Peptide antibodies suggested cross-reaction of specific epitopes between these proteins and pilin. Polyclonal serum to pilus preparations was used to screen colony blots of plasmid pBR322 and plasmid pHC79 gonococcal clone banks and several reactive clones were selected. A 1.2 kb fragment expressing a protein with an approximate mol.wt. of 28,000 was subcloned and expressed. Mutants in the gonococcus were constructed to determine the effect on biological function. PCR analysis will be used to determine sequence conservation among strains. (0 ref)

? log y
23mar01 11:36:50 User219783 Session D1693.2